- Abstract:
-
Objectives
o evaluate the efficacy of etanercept and methotrexate as monotherapies and as combination therapy in subjects with active psoriatic arthritis (PsA).
Methods
he Study of Etanercept and Methotrexate in Combination or as Monotherapy in Subjects with Psoriatic Arthritis (SEAM-PsA) is an ongoing, global, doubleblind, 48-week, randomised, controlled study. Subjects are randomised (1:1:1) to etanercept monotherapy, methotrexate monotherapy or etanercept-metho...
Expand abstract - Publication status:
- Published
- Peer review status:
- Peer reviewed
- Version:
- Publisher's version
- Publisher:
- BMJ Publishing Group Publisher's website
- Journal:
- RMD Open Journal website
- Volume:
- 4
- Issue:
- 1
- Pages:
- e000606
- Publication date:
- 2018-02-03
- Acceptance date:
- 2017-12-19
- DOI:
- EISSN:
-
2056-5933
- Pubs id:
-
pubs:827068
- URN:
-
uri:51397a63-3977-447d-9bef-f2de465fec0d
- UUID:
-
uuid:51397a63-3977-447d-9bef-f2de465fec0d
- Local pid:
- pubs:827068
- Language:
- English
- Keywords:
- Copyright holder:
- Coates et al
- Copyright date:
- 2018
- Notes:
-
© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted. This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Journal article
Design and rationale of the Study of Etanercept and Methotrexate in Combination or as Monotherapy in Subjects with Psoriatic Arthritis (SEAM-PsA)
Actions
Authors
Funding
Amgen
More from this funder
Bibliographic Details
Item Description
Terms of use
Metrics
Altmetrics
Dimensions
If you are the owner of this record, you can report an update to it here: Report update to this record